NBIX

Neurocrine Biosciences, Inc. develops treatments for rare and under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company has a portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis, and uterine fibroids. Neurocrine also has a pipeline of compounds in mid-to-late phase clinical development across its core therapeutic areas, focusing on fulfilling unmet medical needs in these patient populations.